<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762342</url>
  </required_header>
  <id_info>
    <org_study_id>4168624</org_study_id>
    <nct_id>NCT04762342</nct_id>
  </id_info>
  <brief_title>Exercise and Neuroprotection in Older Persons With Multiple Sclerosis</brief_title>
  <official_title>Exercise and Neuroprotection in Older Persons With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study seeks to investigate whether 24 weeks of power training has neuroprotective effects&#xD;
      in older PwMS. Additional purposes are to examine whether older PwMS have blunted exercise&#xD;
      adaptations, compared to age- and gender-matched healthy controls, and to investigate whether&#xD;
      the potential effects of power training are maintained after 24 weeks of follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the past 3-4 decades, the lifespan among people with multiple sclerosis (MS) has&#xD;
      increased substantially. Today more than one-third of all people with MS are 60 years or&#xD;
      older. With advanced age, people with MS are more likely to have impairments in cognitive and&#xD;
      physical function.&#xD;
&#xD;
      Positive adaptations within the nervous system (~neuroplasticity) have been shown to occur in&#xD;
      people with MS following periods of resistance training (RT). This resembles the observations&#xD;
      in young and old healthy individuals. Moreover, a specific type of RT termed power training&#xD;
      appears to be particularly beneficial, as it emphasizes an explosive concentric phase of&#xD;
      muscle contraction. This taxes the nervous system to a very high extent. As a result, power&#xD;
      training has been shown to improve several aspects that rely on the nervous system in older&#xD;
      individuals without MS. These aspects include cognition, neuromuscular function, and physical&#xD;
      function.&#xD;
&#xD;
      The investigators speculate that older people with MS would also benefit. However, no studies&#xD;
      have looked into the effects of power training in older people with MS. Moreover, it is not&#xD;
      known if the effects of power training are blunted, compared to healthy age- and&#xD;
      gender-matched healthy individuals due to the marked neurodegeneration that characterizes&#xD;
      older MS (transient/permanent damage to CNS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage brain volume change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Whole brain atrophy will be measured from MRI-scans.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalized gray and white matter volume change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>MRI scan</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hippocampus volume change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>MRI scan.</description>
  </other_outcome>
  <other_outcome>
    <measure>Thalamus volume change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>MRI scan.</description>
  </other_outcome>
  <other_outcome>
    <measure>Corpus callosum volume change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>MRI scan.</description>
  </other_outcome>
  <other_outcome>
    <measure>Basal Ganglia volume change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>MRI scan.</description>
  </other_outcome>
  <other_outcome>
    <measure>Glial fibrillary acidic protein (GFAP) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Resting blood sample- Marker of neurodegeneration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurofilament light chain (NfL) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Resting blood sample-Marker of neurodegeneration:</description>
  </other_outcome>
  <other_outcome>
    <measure>Brain-derived neurotrophic factor (BDNF) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Resting blood sample-Neurotrophic factor.</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin-like growth factor-1 (IGF).</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Resting blood sample-Neurotrophic factor.</description>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive protein (CRP) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Resting blood sample-Inflammatory markers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Interleukin-6 (IL-6) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Resting blood sample-Inflammatory markers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor necrosis alpha (TNF-alpha) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Resting blood sample-Inflammatory markers.</description>
  </other_outcome>
  <other_outcome>
    <measure>C-terminal collagen cross-links (CTX) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Resting blood sample- Bone turnover markers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Type-1n-terminal propeptide (P1NP) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Resting blood sample- Bone turnover markers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Bone mineral density of the femoral neck and lumbar spine change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Dexa scan.</description>
  </other_outcome>
  <other_outcome>
    <measure>Body composition change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Dexa scan- whole body scan.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognition change .</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Selective Reminding Test (memory) and Symbol Digit Modalities Test (processing speed).</description>
  </other_outcome>
  <other_outcome>
    <measure>Nine step stair test change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks</time_frame>
    <description>Time to climb a 9 step flight of stairs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Six Spot Step Test (SSST) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>SSST is a measure of walking ability, balance and coordination. Measured as the time to complete the course.</description>
  </other_outcome>
  <other_outcome>
    <measure>Six-minute walk test (&amp;MWT) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Distance covered on a 30 meter track during six minutes maximal walking. Distance covered each minute is noted.</description>
  </other_outcome>
  <other_outcome>
    <measure>Timed 25-Feet Walk Test (T25FWT) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Time to walk 25 feet (normal walk and maximal walk pace).</description>
  </other_outcome>
  <other_outcome>
    <measure>Short Physical performance battery change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Composite score from Five Times Sit- to- Stand Test, Tandem Test and 3 meter walk test.</description>
  </other_outcome>
  <other_outcome>
    <measure>Maximal Voluntary Contraction (MVC) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>The following muscle groups are tested: Knee flexors, Knee extensors, Plantor flexor and Dorsal flexor.</description>
  </other_outcome>
  <other_outcome>
    <measure>Dynamic Strength change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>The following muscle groups are tested: Knee flexors, Knee extensors, Plantor flexor and Dorsal flexor.</description>
  </other_outcome>
  <other_outcome>
    <measure>Force Steadiness change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>The following muscle groups are tested: Plantor flexor and Dorsal flexor.</description>
  </other_outcome>
  <other_outcome>
    <measure>Interpolated Twitch Technology change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Knee extensors are tested.</description>
  </other_outcome>
  <other_outcome>
    <measure>Grip strength change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Measured by Hand Dynamoter.</description>
  </other_outcome>
  <other_outcome>
    <measure>SF-12 change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Patient Reported Outcome Measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pittsburg Sleep Qulity Index change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Patient Reported Outcome Measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Brief pain inventory change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Patient Reported Outcome Measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Baecke Physical Activity change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Patient Reported Outcome Measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>HADS change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Patient Reported Outcome Measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Patient Reported Outcome Measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>FES-I change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>Patient Reported Outcome Measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Multiple Sclerosis Impact Scale (MSIS-29) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks .</time_frame>
    <description>Patient Reported Outcome Measure (only applicable for people with MS).</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Fatigue Impact Scale (MFIS) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks .</time_frame>
    <description>Patient Reported Outcome Measure (only applicable for people with MS).</description>
  </other_outcome>
  <other_outcome>
    <measure>12-Item MS walking Scale (MSWS-12) change.</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks .</time_frame>
    <description>Patient Reported Outcome Measure (only applicable for people with MS).</description>
  </other_outcome>
  <other_outcome>
    <measure>Expanded Disability Status Scale (only applicable for people with MS).</measure>
    <time_frame>Baseline, after 24 weeks and after 48 weeks.</time_frame>
    <description>The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a trained exercise physiologist.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Sclerosis</condition>
  <condition>Demyelinating Autoimmune Diseases, CNS</condition>
  <condition>Autoimmune Diseases of the Nervous System</condition>
  <condition>Demyelinating Diseases</condition>
  <condition>Healthy Aging</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Training Group Multiple Sclerosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of moderate to high-intensity power training (resistance training- emphasizing an explosive concentric phase of muscle contraction) performed twice weekly.&#xD;
Balance- and functional exercises are included from week 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group Multiple Sclerosis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Habitual lifestyle including standard care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Training Group Healty Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of moderate to high-intensity power training (resistance training- emphasizing an explosive concentric phase of muscle contraction) performed twice weekly.&#xD;
Balance and functional exercises are included from week 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group Healthy Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Habitual lifestyle</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Resistance training (Power training)</intervention_name>
    <description>All sessions will start with a brief warm up on a stationary bike and uni-lateral knee raises.&#xD;
Power training: Involves exercises in which participants has to focus on performing fast/explosive muscle contraction during the concentric phase, and slow/controlled (approximately 2-3 s) muscle contraction during the eccentric phase.&#xD;
Functional- and balance exercises are included from week 10-24.&#xD;
Set, repetition, and load:&#xD;
Week 1-4: 3 sets of 15 repetitions at a load of 15 repetitions maximum (RM). Week 5-14: 3 sets of 12 repetitions at a load of 12 RM. Week 15-24: 3 sets of 10 repetitions at a load of 10 RM.&#xD;
Strengthening exercises:&#xD;
Bilateral leg press&#xD;
Bilateral plantar flexion (performed in leg press machine)&#xD;
Knee extension&#xD;
Dorsal flexion (Theraband gold resistance band (Theraband, Akron, OH, US))&#xD;
Seated crunches on exercise ball (Theraband gold resistance band (Theraband, Akron, OH, US)).&#xD;
Seated back extension lower back</description>
    <arm_group_label>Training Group Healty Control</arm_group_label>
    <arm_group_label>Training Group Multiple Sclerosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed consent&#xD;
&#xD;
          -  Clinical MS diagnosis according to the McDonald criteria (only applicable for PwMS)&#xD;
&#xD;
          -  EDSS ≤6.5 (only applicable for PwMS)&#xD;
&#xD;
          -  Able to transport themselves to the testing sessions in Aarhus&#xD;
&#xD;
          -  Able to transport themselves to training, if randomized to the training group&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Comprise comorbidities (cardiovascular-, respiratory-, orthopedic- or other&#xD;
             neurological diseases&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Metallic implant that prevents MRI scans&#xD;
&#xD;
          -  Participation in structured RT or power training for the past 3 months (&gt; 1 session&#xD;
             per week)&#xD;
&#xD;
          -  Cognitive impairments (The participant is not able to understand and follow training-&#xD;
             and testing instructions)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Louise K. Jørgensen, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Exercise Biology, Department of Public Health, Aarhus University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Louise K. Jørgensen, MSc</last_name>
    <phone>+45 22292062</phone>
    <email>mlkj@ph.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Exercise Biology, Department of Public Health, Aarhus University</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Louise K. Jørgensen, Msc</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Hurwitz BJ. Analysis of current multiple sclerosis registries. Neurology. 2011 Jan 4;76(1 Suppl 1):S7-13. doi: 10.1212/WNL.0b013e31820502f6. Review.</citation>
    <PMID>21205683</PMID>
  </reference>
  <reference>
    <citation>Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler. 2008 Sep;14(8):1091-8. doi: 10.1177/1352458508092263.</citation>
    <PMID>18728060</PMID>
  </reference>
  <reference>
    <citation>Hvid LG, Strotmeyer ES, Skjødt M, Magnussen LV, Andersen M, Caserotti P. Voluntary muscle activation improves with power training and is associated with changes in gait speed in mobility-limited older adults - A randomized controlled trial. Exp Gerontol. 2016 Jul;80:51-6. doi: 10.1016/j.exger.2016.03.018. Epub 2016 Apr 14.</citation>
    <PMID>27090485</PMID>
  </reference>
  <reference>
    <citation>Aagaard P, Suetta C, Caserotti P, Magnusson SP, Kjaer M. Role of the nervous system in sarcopenia and muscle atrophy with aging: strength training as a countermeasure. Scand J Med Sci Sports. 2010 Feb;20(1):49-64. doi: 10.1111/j.1600-0838.2009.01084.x. Review.</citation>
    <PMID>20487503</PMID>
  </reference>
  <reference>
    <citation>Schoenfeld BJ, Contreras B, Willardson JM, Fontana F, Tiryaki-Sonmez G. Muscle activation during low- versus high-load resistance training in well-trained men. Eur J Appl Physiol. 2014 Dec;114(12):2491-7. doi: 10.1007/s00421-014-2976-9. Epub 2014 Aug 12.</citation>
    <PMID>25113097</PMID>
  </reference>
  <reference>
    <citation>Best JR, Chiu BK, Liang Hsu C, Nagamatsu LS, Liu-Ambrose T. Long-Term Effects of Resistance Exercise Training on Cognition and Brain Volume in Older Women: Results from a Randomized Controlled Trial. J Int Neuropsychol Soc. 2015 Nov;21(10):745-56. doi: 10.1017/S1355617715000673.</citation>
    <PMID>26581787</PMID>
  </reference>
  <reference>
    <citation>Liu-Ambrose T, Nagamatsu LS, Graf P, Beattie BL, Ashe MC, Handy TC. Resistance training and executive functions: a 12-month randomized controlled trial. Arch Intern Med. 2010 Jan 25;170(2):170-8. doi: 10.1001/archinternmed.2009.494.</citation>
    <PMID>20101012</PMID>
  </reference>
  <reference>
    <citation>Reid KF, Martin KI, Doros G, Clark DJ, Hau C, Patten C, Phillips EM, Frontera WR, Fielding RA. Comparative effects of light or heavy resistance power training for improving lower extremity power and physical performance in mobility-limited older adults. J Gerontol A Biol Sci Med Sci. 2015 Mar;70(3):374-80. doi: 10.1093/gerona/glu156. Epub 2014 Sep 8.</citation>
    <PMID>25199912</PMID>
  </reference>
  <reference>
    <citation>Caserotti P, Aagaard P, Larsen JB, Puggaard L. Explosive heavy-resistance training in old and very old adults: changes in rapid muscle force, strength and power. Scand J Med Sci Sports. 2008 Dec;18(6):773-82. doi: 10.1111/j.1600-0838.2007.00732.x. Epub 2008 Jan 30.</citation>
    <PMID>18248533</PMID>
  </reference>
  <reference>
    <citation>Bottaro M, Machado SN, Nogueira W, Scales R, Veloso J. Effect of high versus low-velocity resistance training on muscular fitness and functional performance in older men. Eur J Appl Physiol. 2007 Feb;99(3):257-64. Epub 2006 Dec 5.</citation>
    <PMID>17146693</PMID>
  </reference>
  <reference>
    <citation>Earles DR, Judge JO, Gunnarsson OT. Velocity training induces power-specific adaptations in highly functioning older adults. Arch Phys Med Rehabil. 2001 Jul;82(7):872-8.</citation>
    <PMID>11441371</PMID>
  </reference>
  <reference>
    <citation>Henwood TR, Riek S, Taaffe DR. Strength versus muscle power-specific resistance training in community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2008 Jan;63(1):83-91.</citation>
    <PMID>18245765</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Healthy aging</keyword>
  <keyword>Exercise</keyword>
  <keyword>Neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Demyelinating Diseases</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Autoimmune Diseases of the Nervous System</mesh_term>
    <mesh_term>Demyelinating Autoimmune Diseases, CNS</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

